eribulin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in INTENSITY THERAPEUTICS's portfolio. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
biotech · Breast Cancer · Sarcoma,Soft Tissue · INTS
INTENSITY THERAPEUTICS
INTENSITY THERAPEUTICS, INC.
INTENSITY THERAPEUTICS drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Shelton, USA HQ
2012 Founded
12 Employees
Public company Type
INTS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Shelton, USA
- Founded
- 2012
- Employees
- 12
- Programs
- 6
- Drugs
- 9
- Patents
- 3
INTENSITY THERAPEUTICS pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
INTENSITY THERAPEUTICS drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to INTENSITY THERAPEUTICS in public FDA and regional records.
-
Development asset linked to INTENSITY THERAPEUTICS in public FDA and regional records.
-
pazopanib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in INTENSITY THERAPEUTICS's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to INTENSITY THERAPEUTICS in public FDA and regional records.
-
Development asset linked to INTENSITY THERAPEUTICS in public FDA and regional records.
-
Development asset linked to INTENSITY THERAPEUTICS in public FDA and regional records.
-
trabectedin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor